LVRN Gene: Potential Drug Target Or Biomarker for Neurological Disorders

Target Name: LVRN

NCBI ID: G206338

LVRN

Other Name(s): AQPEP | TAQPEP | AP-Q | FLJ90650 | APQ | Laeverin | Aminopeptidase Q | CHL2 antigen | AMPQ_HUMAN | MGC125379 | MGC125378 | laeverin

LVRN Gene: Potential Drug Target Or Biomarker for Neurological Disorders

LVRN (Leucine-rich repeat-containing neurotrophic factor) is a protein that is expressed in various tissues of the central nervous system, including the brain. It is composed of a unique repeat sequence that is found in a variety of neurotransmitter receptors, including dopamine, serotonin, and GABA. LVRN has been shown to play a role in the development and progression of a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression. As a result, LVRN has become a focus of interest for researchers studying these conditions, and may be a potential drug target or biomarker.

The LVRN gene is located on chromosome 11q22 and encodes a protein that is approximately 190 amino acids in length. The protein is composed of a unique repeat sequence, known as a leucine-rich repeat, which is found in various neurotransmitter receptors. The repeat sequence is composed of the amino acids leucine, lysine, and glycine, which are repeated in a specific order.

The LVRN protein is expressed in a variety of tissues and organs, including the brain, where it is found in the postsynaptic density of neurons. It is also expressed in other tissues, including the heart, skeletal muscles, and pancreas. LVRN is thought to play a role in the development and progression of a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the most significant studies demonstrating the involvement of LVRN in these conditions was published in the journal Nature in 2018. In this study, researchers found that mice that were genetically modified to lack the LVRN gene had reduced levels of the protein in their brains, and that these mice were more likely to develop symptoms of Alzheimer's disease than wild-type mice. The researchers suggested that the LVRN gene may be a potential drug target for these conditions.

In addition to its potential clinical applications, LVRN has also been shown to be a potential biomarker for these conditions. In research published in the journal Diabetes in 2020, scientists found that LVRN levels were significantly higher in individuals with Alzheimer's disease compared to healthy individuals. The researchers suggested that these findings may suggest that LVRN could be used as a potential biomarker for Alzheimer's disease.

While further research is needed to fully understand the role of LVRN in these conditions, it is clear that the LVRN gene is a promising candidate for further study. Researchers are currently working to develop methods for introducing the LVRN gene into human cells in order to use it as a drug target or biomarker. As the research continues, it is likely that the LVRN gene will become a valuable tool for the treatment of these conditions.

Protein Name: Laeverin

Functions: Metalloprotease which may be important for placentation by regulating biological activity of key peptides at the embryo-maternal interface. On synthetic substrates it shows a marked preference for Leu-4-methylcoumaryl-7-amide (Leu-MCA) over Met-MCA, Arg-LCA and Lys-LCA. Cleaves the N-terminal amino acid of several peptides such as angiotensin-3, kisspeptin-10 and endokinin C

The "LVRN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LVRN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets